These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20603149)

  • 1. Lymphocyte activation in type 1 diabetes mellitus: the increased significance of Kv1.3 potassium channels.
    Toldi G; Vásárhelyi B; Kaposi A; Mészáros G; Pánczél P; Hosszufalusi N; Tulassay T; Treszl A
    Immunol Lett; 2010 Sep; 133(1):35-41. PubMed ID: 20603149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-lymphocyte calcium influx characteristics and their modulation by Kv1.3 and IKCa1 channel inhibitors in the neonate.
    Toldi G; Treszl A; Pongor V; Gyarmati B; Tulassay T; Vásárhelyi B
    Int Immunol; 2010 Sep; 22(9):769-74. PubMed ID: 20601376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis.
    Toldi G; Bajnok A; Dobi D; Kaposi A; Kovács L; Vásárhelyi B; Balog A
    Immunobiology; 2013 Mar; 218(3):311-6. PubMed ID: 22705192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different calcium influx characteristics upon Kv1.3 and IKCa1 potassium channel inhibition in T helper subsets.
    Orbán C; Bajnok A; Vásárhelyi B; Tulassay T; Toldi G
    Cytometry A; 2014 Jul; 85(7):636-41. PubMed ID: 24827427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocyte calcium influx characteristics and their modulation by Kv1.3 and IKCa1 channel inhibitors in healthy pregnancy and preeclampsia.
    Toldi G; Stenczer B; Treszl A; Kollár S; Molvarec A; Tulassay T; Rigó J; Vásárhelyi B
    Am J Reprod Immunol; 2011 Feb; 65(2):154-63. PubMed ID: 20649894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocyte calcium influx kinetics in multiple sclerosis treated without or with interferon β.
    Toldi G; Folyovich A; Simon Z; Zsiga K; Kaposi A; Mészáros G; Tulassay T; Vásárhelyi B
    J Neuroimmunol; 2011 Aug; 237(1-2):80-6. PubMed ID: 21764463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium influx kinetics, and the features of potassium channels of peripheral lymphocytes in primary Sjögren's syndrome.
    Legány N; Toldi G; Orbán C; Megyes N; Bajnok A; Balog A
    Immunobiology; 2016 Nov; 221(11):1266-72. PubMed ID: 27346388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of Kv1.3 and IKCa1 channel inhibition on cytokine production and calcium influx of T lymphocytes in rheumatoid arthritis and ankylosing spondylitis.
    Toldi G; Munoz L; Herrmann M; Schett G; Balog A
    Immunol Res; 2016 Apr; 64(2):627-31. PubMed ID: 26280090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis by flow cytometry of calcium influx kinetics in peripheral lymphocytes of patients with rheumatoid arthritis.
    Bajnok A; Kaposi A; Kovács L; Vásárhelyi B; Balog A; Toldi G
    Cytometry A; 2013 Mar; 83(3):287-93. PubMed ID: 23335202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kv1.3 channels as a potential target for immunomodulation of CD4+ CD28null T cells in patients with acute coronary syndrome.
    Xu R; Cao M; Wu X; Wang X; Ruan L; Quan X; Lü C; He W; Zhang C
    Clin Immunol; 2012 Feb; 142(2):209-17. PubMed ID: 22169811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel alpha-KTx peptides from the venom of the scorpion Centruroides elegans selectively blockade Kv1.3 over IKCa1 K+ channels of T cells.
    Olamendi-Portugal T; Somodi S; Fernández JA; Zamudio FZ; Becerril B; Varga Z; Panyi G; Gáspár R; Possani LD
    Toxicon; 2005 Sep; 46(4):418-29. PubMed ID: 16026809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
    Bagdány M; Batista CV; Valdez-Cruz NA; Somodi S; Rodriguez de la Vega RC; Licea AF; Varga Z; Gáspár R; Possani LD; Panyi G
    Mol Pharmacol; 2005 Apr; 67(4):1034-44. PubMed ID: 15615696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of aging on calcium influx and potassium channel characteristics of T lymphocytes.
    Kollár S; Berta L; Vásárhelyi ZE; Balog A; Vásárhelyi B; Rigó J; Toldi G
    Oncotarget; 2015 May; 6(15):13750-6. PubMed ID: 25948778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Answer to the "comment on functional consequences of Kv1.3 ion channel rearrangement into the immunological synapse" by Stefan Bittner et al. [Immunol. Lett. 125 (Aug 15 (2)) (2009) 156-157].
    Hajdú P; Szilágyi O; Tóth A; Krasznai Z; Pocsai K; Panyi G
    Immunol Lett; 2010 Mar; 129(1):47-9. PubMed ID: 20079762
    [No Abstract]   [Full Text] [Related]  

  • 15. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
    Rangaraju S; Chi V; Pennington MW; Chandy KG
    Expert Opin Ther Targets; 2009 Aug; 13(8):909-24. PubMed ID: 19538097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional consequences of Kv1.3 ion channel rearrangement into the immunological synapse.
    Tóth A; Szilágyi O; Krasznai Z; Panyi G; Hajdú P
    Immunol Lett; 2009 Jun; 125(1):15-21. PubMed ID: 19477198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium Influx Kinetics and the Characteristics of Potassium Channels in Peripheral T Lymphocytes in Systemic Sclerosis.
    Toldi G; Legány N; Ocsovszki I; Balog A
    Pathobiology; 2020; 87(5):311-316. PubMed ID: 32911471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
    Beeton C; Wulff H; Barbaria J; Clot-Faybesse O; Pennington M; Bernard D; Cahalan MD; Chandy KG; Béraud E
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13942-7. PubMed ID: 11717451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kv1.3 lymphocyte potassium channel inhibition as a potential novel therapeutic target in acute ischemic stroke.
    Folyovich A; Biro E; Orban C; Bajnok A; Vasarhelyi B; Toldi G
    CNS Neurol Disord Drug Targets; 2014; 13(5):801-6. PubMed ID: 25012622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium channels as therapeutic targets for autoimmune disorders.
    Wulff H; Beeton C; Chandy KG
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):640-7. PubMed ID: 14579513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.